logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
26/08/2025
European stock index futures fell, with Euro Stoxx 50 index futures dropping by 0.6%, Germany's DAX index futures falling by 0.5%, and UK's FTSE 100 index futures down by 0.4%.
Latest
3 m ago
The yield on the 30-year US Treasury bond continued to decline, rising 5 basis points to 4.94%.
3 m ago
SAIC Group's joint brand Wuling and MG's first joint experiential center abroad is located in Indonesia.
3 m ago
The UK 30-year government bond yield rose by 7.6 basis points to 5.624%, reaching a new high since August 19. The UK 2-year government bond yield increased by 6 basis points to 4.008%.
4 m ago
The French CAC 40 index continued its decline from Monday, with the drop widening to 1.9%.
4 m ago
Gilead Sciences announced on Tuesday that its once-yearly injectable drug for HIV prevention has received marketing approval from the European Commission. The drug, known as lenacapavir, will be marketed under the brand name Yeytuo in Europe. The drug was approved by US regulators in June for sale in the US under the name Yeztugo. The approval by the European Commission applies to the 27 EU member states, as well as Norway, Iceland, and Liechtenstein. Before providing the drug to patients, Gilead will need to negotiate pricing and reimbursement terms with the healthcare systems of each country. Analysts predict that annual sales of this drug will exceed $4 billion by 2029. The approval by the European Commission allows for the use of this drug as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection through sexual transmission for adults and adolescents at high risk of infection with the deadly virus.
See all latestmore
logo
Contact US
qr
+852 - 60190728
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.